Abstract 358P
Background
Current treatment guidelines state that resectable early stage NSCLC may be treated with adjuvant therapy in the form of chemotherapy and radiotherapy. For Nonsquamous Non-Small Cell Lung Cancer (NS NSCLC), Epidermal Growth Factor Receptor (EGFR) mutations may be present in up to 60% of cases. In the locally advanced and metastatic settings, EGFR tyrosine kinase inhibitors (TKI) have shown remarkable efficacy. With the basis of EGFR as a driver mutation for carcinogenesis, EGFR TKI treatment has been explored in several studies. However, the role of EGFR TKI in the adjuvant setting remains controversial due to lack of conclusive evidence. The latest treatment guidelines do not favor adjuvant EGFR TKI for EGFR-mutant resected early stage NS-NSCLC. Therefore, this meta-analysis evaluated existing randomized controlled trials (RCTs) for a more precise estimate of the efficacy of adjuvant EGFR TKI and associated lung cancer survival.
Methods
A systematic search of Pubmed, Embase, Cochrane, and clinical trials databases as well as hand search were utilized to identify RCTs investigating adjuvant EGFR TKI treatment in resected NS-NSCLC.
Results
Seven RCTs were included (N=2095), all contain disease free survival (DFS) data. Four trials gave EGFR TKI treatment for 24 months, while one trial provided EGFR TKI treatment for 36 months. Erlotinib, gefitinib, icotinib, and osimertinib were the EGFR TKI used in the RCTs. Treatment with adjuvant EGFR TKI showed statistically significant DFS benefit (HR 0.64, 95% CI[0.50-0.82)], P=0.0005) although with substantial heterogeneity (I2=98%, P<0.00001). This heterogeneity was attributed to trial phase and EGFR TKI generation used. Subgroup analyses were done for trial phase, treatment duration, disease stage, type of EGFR TKI, and toxicity. It was found that use of EGFR TKI gefinitib has statistically significant survival (DFS) advantage (HR 0.56, 95% CI(0.47-0.66), P<0.00001; I2=0%).
Conclusions
Results of this meta-analysis provide preliminary but strong evidence recommending EGFR TKI in the adjuvant setting among EGFR-mutant resected early NS NSCLC by improving DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session